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The Brugada syndrome (BrS) and the long QT syndrome are the most frequently diagnosed
genetically-conditioned arrhythmogenic syndromes. It is a primary disorder of electric cardiac
activity which is demonstrated by elevation of the ST segment in the right precordial leads
connected to an increased risk of sudden death in patients without a structural damage of the
heart. In this article, an overview of genetic heterogeneity, pathophysiology, ECG diagnostics
and therapy possibilities are discussed, including the innovations of the recent years. A brief
case report of a patient presenting with syncope and ST segment elevation is described.
& 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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The Brugada syndrome (BrS) was named after two Spanish
brothers – cardiologists Pedro, Josep Brugara, who is thech Society of Cardiology.
217.
. Bolek).specialist in Cardiac Arrhythmias, General Cardiology, Cardi-
ovascular Diseases and Sports Cardiology. The third man on
the photo is their brother Ramon Brugada who cooperated
with them in many studies and was appointed to be DirectorPublished by Elsevier Urban & Partner Sp.z o.o. All rights reserved..
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Girona, Spain (Fig. 1). The syndrome is characterized by
abnormal electrocardiogram (ECG) ﬁndings and an increased
risk of sudden cardiac death (Fig. 2) [1,2]. The Brugada
syndrome was ﬁrst found and reported among survivors
who suffered cardiac arrest in 1989 [3]. In 1992, Brugadas
described a crucial work dealing with a case-series of 8 patients
who died a sudden cardiac death [4,5]. “The syndrome typically
manifests during adulthood, with a mean age at the time of sudden
death of 41715 years, but it occurs in infants and children also” [6].
BrS is the most common cause of sudden death of young ;Thai
men without previously known cardiac disease [5]. WorldwideFig. 1 – The three brothers, cardiologists Pedro, Josep and
Ramon Brugada (with the consent of Brugada R.).
Fig. 2 – Brugada syndrome type 1. One of the ﬁrst ECG strip wh
Dr.Číhalík.prevalence of BrS is E1 in 10,000, but it is much higher in Asian
countries, reaching 5–10 in 10,000 [6,7].2. Genetic heterogeneity and pathophysiology
Approximately 20% of the cases of the Brugada syndrome
have been associated with mutations in the gene SCN5A [8]
which encoding forming the α-subunit of the cardiac sodium
channel (hNav1.5). (Fig. 3) that encodes the sodium ion
channel in the cell membranes – the myocytes [9]. A location
of this gene is on the short arm of the third chromosome
(3p21) [10]. This gene contains mutations which might lead to
a loss of the action potential dome of some epicardial areas of
the right ventricle, which in turn results in transmural and
epicardial dispersion of repolarization. The transmural dis-
persion is responsible for the ST-segment elevation and also
the development of a vulnerable window in the ventricular
wall, while the epicardial dispersion of repolarization lies
behind the development of phase 2 reentry, which generates
a phase 2 reentrant extrasystole. An extrasystole captures the
vulnerable window to precipitate ventricular tachycardia
and/or ﬁbrillation that often results in sudden cardiac death
[11]. So far over 160 mutations in the SCN5A gene have been
discovered. Each of them has different ways of functioning
and affecting the organism, which explains an expression of
this disorder and the varying degrees of penetration [12,13].
Antzelevitch has recently identiﬁed mutations in the
L-type calcium channel subunits (CACNA1C (A39V and
G490R) and CACNB2 (S481L)) which lead to ST elevation and
a relatively short QT interval (below 360 ms) [14]. Thisere Mr. Brugada described Brugada syndrome, courtesy of
Fig. 3 – Location of the gene SCN5A in the third chromosome.
(Freely redrawn according to Dr. Jonas de Jong's picture http://
en.ecgpedia.org/wiki/File:Scn5a.jpg).
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 5 2 5 – e 5 3 2 e527mutation is inherited in an autosomal dominant pattern and
is more frequently found in males mainly in Asian
populations.
Ishikawa et al. (in 5/2012) discovered a new pathogenic subs-
trate for BrS. They tested signiﬁcance of the identiﬁed mutations
of sarcolemmal membrane–associated protein (SLMAP), which is
one of components of T-tubules and sarcoplasmic reticulum.
Their right cooperation is necessary for a good contraction of
cardiomyocytes [15,16] Abnormalities in these components can
cause ventricular arrhythmias [17–19]. The disease-associated
SLMAP mutations (they identiﬁed 2 SLMAP missense mutations
associated with BrS) do not affect the voltage dependence in
inactivation or activation proﬁles, do not biophysically alter the
hNav1.5 channel gating, but impaired the cell surface expression
of hNav1.5 and reduced the inward sodium current in trans-
fected cells and BrS susceptibility [15].H. Liu et al. recently report the study of genetic and
functional anomalies of mutations in the TRPM4 gene, which
code the transient receptor potential cation channel subfamily
M member 4 (hTRPM4), known as melastatin-4, the gene is
located on chromosome 19 (19q13.33) [20,21]. It is a calcium-
activated nonselective cation channel and has been recently
found in families with progressive cardiac conductance dis-
turbances [22]. The results of study suggest that TRPM4
mutations accounts for about 2.7–6% of BrS cases. Surprising
is that mutations in TRPM4 not only leads to reduction and
loss of current density, but in some cases to increase its
effectiveness [20]. The situation is complicated by the fact
that TRPM4 is expressed in various tissues and can affect the
neuro-hormonal regulation or cardiac development [23,24].3. Clinical features
The complete syndrome is characterized by episodes of fast
polymorphic ventricular tachycardia (VT) (Fig. 4) in patients
with an electrocardiogram showing a pattern of right bundle
branch block and ST segment elevation in leads V1 to V3.
If only a short VT occurs, the patient may experience either
vertigo or syncope. If the VT is long lasting or ventricular
ﬁbrillation (VF) develops, cardiac arrest or sudden death may
be a sequelae [25].
In 2012 Jeevaratnam et al. published the results of their
study “Frequency distribution analysis of activation times and
regional ﬁbrosis in murine Scn5a(þ/ ) hearts: The effects of
ageing and sex”. They found a greater occurrence of the bundle
branch block in all Scn5a(þ/ ) mice compared to wildtype
mice which directly correlated with histomorphometric assess-
ment of regional ﬁbrosis in both septa and free walls, prefer-
entially involving the RV. This was further modiﬁed by aging
and sex [26].
Priori et al. published an overview of 130 patients with
Brugada syndrome and 70 affected family members. Overall,
SCN5A mutations were identiﬁed in 28 probands; the remain-
ing individuals fulﬁlled accepted diagnostic ECG criteria. Multi-
variate Cox regression analysis showed that, after adjusting
for sex, a family history of sudden cardiac death, and mutation
in SCN5A, the cooccurrence of spontaneous ST segment
elevation in the anterior chest leads of a resting 12-lead ECG
and a personal history of syncope identiﬁed persons at risk for
cardiac arrest [27].
Chockalingam showed that fever and vaccination in chil-
dren may be potential arrhythmia triggers. One of the most
common ﬁnding on ECG is a conduction delay [28].4. Diagnosis
It is possible to diagnose the disease by observing charac-
teristic patterns on an electrocardiogram. BrS has 3 different
ECG patterns. Type 1 is characterized by a prominent coved ST-
segment elevation displaying J wave amplitude or ST-segment
elevation Z2mm or 0.2mV at its peak followed by a negative
T-wave. There is no isoelectric separation. The type 2 is
characterizes also by elevation of ST segment, which is descen-
dent, followed by a positive or biphasic T-wave ( a saddle back
Fig. 4 – Case report: a polymorphic ventricular tachycardia documented on telemetric ECG tracing.
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of o1mm of saddle back type, coved type, or both [6,13].
According to Brugadas, the pattern that was seen on the ECG
suggests persistent ST elevations in the electrocardiographic
leads V1–V3 with the appearance of the right bundle branch
block (RBBB) with or without the terminal S waves in the lateral
leads that are usually associated with a typical RBBB. A pro-
longed PR interval, suggesting a conduction disturbance in
the heart, can also be frequently seen. The electrocardiogram
can ﬂuctuate over time, for example—adrenergic stimulation
decreases the ST segment elevation, while vagal stimulation
worsens it. Second thing is the using of anti-arrhythmic drugs.
The administration of class Ia (ajmaline), Ic (ﬂecainide) and III
drugs increases the ST segment elevation. ST segment elevation
in some patients can be decreased by exercise but it can increase
it in others (after exercise when the body temperature has come
up). The changes in heart rate caused by atrial pacing are
followed by changes in the degree of ST segment elevation.
When heart rate drops, ST segment elevation comes up and vice
versa. However, it can also occur the other way round [25].
In all patients with unexplained syncope, an electrophy-
siological testing should be performed with exception of
those who were resuscitated for VF. In these patients, ICD
implantation as a secondary prevention of sudden death is
indicated as a matter of routine [5,6,27].
Genetic testing for the Brugada syndrome is available
based on a blood sample analysis. This may help to conﬁrm
a diagnosis in patients potentially having the Brugada syn-
drome, as well as differentiate between relatives who are at
risk for the disease and those who are not [13].5. Differential diagnosis
The differential diagnosis of Brugada syndrome is very wide,
since many disease states may cause ST segment elevation
in the right precordial leads in V1–3: an acute myocardial
infarction, a right ventricular infarction, an acute myocarditis,
an acute pulmonary embolism, the right or left bundle branch
block and a left ventricular hypertrophy, the long QT syn-
drome, a premature depolarization syndrome, hypercalcemia,
hyperkalemia, an overdose of tricyclic antidepressants, a
cocaine intoxication, vitamin B1 deﬁciency, a mediastinal
tumor compressing outﬂow tract of the right ventricular,
Duchen's muscular dystrophy, Friedreich's ataxia [13,29].6. Treatment
Ventricular ﬁbrillation or fast polymorphic ventricular tachy-
cardia is the common cause of death in patients with the
Brugada syndrome. These arrhythmias have a sudden onset
without any warning. There is no treatment known that could
reliably and totally prevent ventricular ﬁbrillation in this
syndrome. Implantable cardioverter-deﬁbrillator (ICD) con-
tinuously monitors the heart rhythm and can deﬁbrillate an
individual should the VF occur. Quinidine, a Class Ia antiar-
rhythmic drug, has been found to decrease a number of VF
episodes and to correct spontaneous ECG alterations, possibly
by inhibiting Ito channels [25,30]. On the other hand, some
drugs have been found to induce type-1 ECG and/or potentially
fatal arrhythmias in the Brugada syndrome patients. Avoiding
the use of these drugs, such as propafenone, or using them
only under controlled conditions in BrS patients is strictly
advised [31]. Beta blockers may be useful [28].
Priori et al. (in 2002) suggested a risk stratiﬁcation scheme
designed to target the use of ICD device in patients with BrS
[27]. Some years later (in 2012), they reported the results of
the PRogrammed ELectrical stimUlation preDictive valuE
registry (PRELUDE), a large cohort of patients prospectively
investigated and, where the VT or VF inducibility during
programmed electrical stimulation is not predictive of
arrhythmic events, on the other side the study afﬁrmed the
prognostic value of a spontaneous type I ECG and history of
syncope and above that as ﬁrst in time demonstrated a
ventricular effective refractory period o200 ms and QRS
fragmentation as independent risk indicators. These results
could be basics for a new risk stratiﬁcation scheme for BrS
which could be useful to ﬁnd the suitable patients for
prophylactic implantable cardioverter deﬁbrillator [32].7. Case report: syncope in a patient with
Brugada syndrome with a telemetry-documented
polymorphic ventricular tachycardia
Male patient, born in 1977, with a history of common children
diseases, salmonellosis and allergy (dust, seasonal hay-fever).
He was investigated at emergency department because
of diarrhea. On ECG, ST segment elevation in V1–3 was
Fig. 5 – Case report: 12-lead ECG strip with ST segment elevation in V1–V3.
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heart attack and he was referred to cardiology for coronary
angiogram. As the cardioselective markers were negative, the
angiogram was not performed. BrS was suspected and the
patient was examined when hospitalized at cardiology
department and later on in clinics. Complex investigations
were made including echo, which came out as normal.
Magnetic resonance imaging of the heart was also scheduled.
Before it was done, the patient was admitted after syncope
when resting at home, with lay and professional cardiopul-
monary resuscitation (CPR) performed at home. There were
typical Brugada changes on ECG at the time of admission to
the hospital (Fig. 6). Echo was repeated, again without any
pathological ﬁnding. Neurology examination did not reveal
any abnormality, as did not a brain CT. On the next day, the
patient was resuscitated because of sudden recurrence of
unconsciousness with a polymorphic VT documented on
telemetric ECG tracing (Fig. 4). On the ECG taken 20 min after
the CPR performed at the cardiology department there were
again typical BrS features (Fig. 7). According to the above-
mentioned facts, it was clear that the syncopes wereassociated with the Brugada syndrome and uncomplicated
implantation of ICD was performed. The ECG changes
remained of the same pattern for the rest of the follow up
time. The patient was discharged from hospital without
antiarrhythmic medication. He experienced 2 adequate ICD
shocks during following 7 years and still without any antiar-
rhythmic medication. Fortunately, he remains without any
signiﬁcant further symptoms.8. Conclusion
The Brugada syndrome is a disorder with a high risk of
sudden death. Therefore, it is necessary to take it into
account especially in connection to differential diagnostics
of syncope conditions in younger patients, who also have
abnormalities of the ST segment on the ECG and the normal
echocardiographic ﬁndings. Correctly diagnosed patients
with an implanted cardioverter-deﬁbrillator as the only
effective form of treatment can lead a full-ﬂedged life with
Fig. 6 – Case report: 12-lead ECG strip with ST segment elevation in V1–V3 after the professional cardiopulmonary resuscitation.
Fig. 7 – Case report: ECG 20 min after the professional cardiopulmonary resuscitation (CPR) performed at the cardiology
department.
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for ICD use in patients with a history of cardiopulmonary
resuscitation for ventricular ﬁbrillation, a pharmacologicaltesting is recommended in all patients with a lack of clear
morphological substrate, as some drugs should be avoided in
BrS to decrease number of ICD shocks.
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